Navigation Links
HemoShear Partners with Expression Analysis (EA) to Develop a Human Drug-Induced Vascular Response Database
Date:7/11/2012

CHARLOTTESVILLE, Va., July 11, 2012 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human surrogate systems for discovery and assessment of new drug compounds, today announced a partnership with the genomic services company Expression Analysis (EA) to develop the first comprehensive database for evaluating the vascular pharmacology of new drug compounds. Using HemoShear's human relevant systems, the database will profile how human vascular cells respond at the genomic level to approximately 75 existing drug compounds that span a wide range of drug classes and have been accepted, black-boxed, or withdrawn from the market.

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO )

"Pharmaceutical companies can use this database to establish a true risk profile of their compounds and investigate potential positive or negative effects. A number of diabetes drugs, for example, have been shown to have adverse cardiovascular effects in humans. We can provide insights about the risks associated with continuing development of new compound candidates by comparing to other drugs in our database that are related by class, genomic signature or mechanism of action," said Nicole Hastings, Ph.D., HemoShear's Vice President of Laboratory Operations. "We partnered with EA because its staff's unrivaled gene expression expertise and throughput are essential to HemoShear's successful and timely development of this landmark database."

EA will generate the database's extensive genomic content by sequencing more than 2,000 human RNA samples. The product will be the transcriptome of each sample, which correlates to the state of the vascular cells in response to a specific drug.

"Sequencing the transcriptome can reveal the expressed quantities of protein-coding messages and isoforms of all active genes as well as detect novel post-transcriptional modifications that HemoShear and the scientific community have yet to identify as significant. In contrast, traditional techniques such as microarrays can only detect changes in expression of predetermined genetic content within a more limited dynamic range. Transcriptome sequencing enables HemoShear to develop the most comprehensive and sustainable database for evaluating drug vascular safety and efficacy," said Wendell Jones, Ph.D., Vice President of Statistics and Bioinformatics at EA.

The partnership will also extend to support HemoShear's Division of Quantitative and Computational Sciences.  EA will provide the bioinformatics and computational infrastructure necessary to process the large volume of genomic data in a defined format from the study's several thousand human samples with consistency and speed in order to accelerate the development of the database.

This work is funded by a $4.3 million Phase II Small Business Innovation Research grant from the National Heart, Lung and Blood Institute of the National Institutes of Health.

About EA
EA provides cutting-edge genomic sequencing, gene expression, genotyping, and bioinformatics services to the world's largest pharmaceutical companies, diagnostic test developers, government agencies, and academic labs. All projects are conducted under clinical-grade quality control, ensured through CLIA certification, GLP compliance, and adherence to CLSI guidelines. EA's bioinformatics staff are key contributors to the Food and Drug Administration's MicroArray Quality Control (MAQC) and Sequencing Quality Control (SEQC) studies, which aim to improve standards and quality measures for reliable use of next-generation sequencing and gene expression technologies in clinical practice and regulatory decision-making. As part of its mission to improve human health, EA has donated more than $2.2 million towards academic genomic research grants and its "Leave Your Fingerprint on the Cure" Program for pediatric cancer hosted at the American Society for Human Genetics annual meeting.

About HemoShear LLC
HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  


'/>"/>
SOURCE HemoShear LLC
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. HemoShear to Present at Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) Conference
2. ACORN Research, LLC Announces Partnership with AdeptBio, LLC
3. Dicom Systems and USARAD.com Announce Partnership and Introduce Beta Version of XMRI.com, New System by USARAD.com
4. Palatin Technologies to Present at Windhovers Therapeutic Area Partnerships Conference
5. Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers
6. BioStorage Technologies Partners with Susan G. Komen for the Cure Tissue Bank at IU Simon Cancer Center to Raise Money and Awareness for Breast Cancer Research
7. Cowen Healthcare Royalty Partners Raises $1 Billion
8. Life Technologies Partners With DaAn Gene to Develop and Commercialize Molecular Diagnostic Assays in China
9. CoreLab Partners Opens Office in Tokyo, Japan
10. Unigene Receives 2012 Drug Delivery Partnerships Industry Achievement Award
11. JBT Corporation and Swisslog Enter Into Partnership for Automated Guided Vehicles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2017)... Springs, FL (PRWEB) , ... ... ... Chief Strategic Analyst, Kenny Soulstring, today announced that the stock market news ... specializing in risk assessment diagnostic testing that screens and identifies exposure, progression ...
(Date:7/20/2017)... TX (PRWEB) , ... July 20, 2017 , ... ... focused on health-related quality of life, today announced its full advisory board. The ... also announced the promotion of James Crooks, PhD, former VP of Engineering, to ...
(Date:7/20/2017)... ... , ... Corporate Directors Forum is recognizing six San Diego directors for their ... , The awards will be presented Thursday, September 7th, from 6 to 9 p.m. ... made significantly positive contributions in the boardrooms of some of our region’s most respected ...
(Date:7/18/2017)... ... 18, 2017 , ... Genedata, a leading provider of advanced ... company, has implemented Genedata Biologics ™ to scale-up their bispecific antibody discovery ... Neurodegenerative Diseases. , The need to systematically evaluate large panels of multi-specific ...
Breaking Biology Technology:
(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/17/2017)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... Report on Form 10-K on Thursday April 13, 2017 with the ... The ... section of the Company,s website at http://www.nxt-id.com  under "SEC Filings," ... 2016 Year Highlights: Acquisition of ...
Breaking Biology News(10 mins):